This report was first published by Endpoints News. To see the original version, click here
SAN FRANCISCO — Shanghai Fosun Pharmaceutical, a major Chinese healthcare manufacturer, aims to build itself into a global drug innovator, an executive with the company told Endpoints News at the JP Morgan Healthcare Conference.
The company — whose businesses include diagnostics, drug development and medical devices — generated $5.9 billion in revenue in 2024. Fosun Pharma co-president Xingli Wang said it has poured money into developing oncology, autoimmune and neurodegenerative drugs over the last decade.
您已阅读23%（601字），剩余77%（2057字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。